首页> 外文期刊>Nutrition Journal >Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials
【24h】

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials

机译:姜黄和姜黄素在心血管危险因素患者降低血脂水平中的功效和安全性:随机对照试验的荟萃分析

获取原文
获取外文期刊封面目录资料

摘要

Dyslipidemia is an important and common cardiovascular risk factor in the general population. The lipid-lowering effects of turmeric and curcumin are unconfirmed. We performed a meta-analysis to assess the efficacy and safety of turmeric and curcumin in lowering blood lipids in patients at risk of cardiovascular disease (CVD). A comprehensive literature search was conducted on PubMed, Embase, Ovid, Medline and Cochrane Library databases to identify randomized controlled trials (published as of November 2016) that assessed the effect of turmeric and curcumin on blood lipid levels including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the effect. The analysis included 7 eligible studies (649 patients). Turmeric and curcumin significantly reduced serum LDL-C (SMD?=?-0.340, 95% confidence interval [CI]: -0.530 to -0.150, P??0.0001) and TG (SMD?=?-0.214, 95% CI: -0.369 to -0.059, P?=?0.007) levels as compared to those in the control group. These may be effective in lowering serum TC levels in patients with metabolic syndrome (MetS, SMD?=?-0.934, 95% CI: -1.289 to -0.579, P??0.0001), and turmeric extract could possibly have a greater effect on reducing serum TC levels (SMD?=?-0.584, 95% CI: -0.980 to -0.188, P?=?0.004); however, the efficacy is yet to be confirmed. Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies. Turmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels. Curcumin may be used as a well-tolerated dietary adjunct to conventional drugs. Further research is required to resolve uncertainties related to dosage form, dose and medication frequency of curcumin.
机译:血脂血症是一般人群中重要且常见的心血管危险因素。姜黄和姜黄素的降脂效果是未经证实的。我们进行了荟萃分析,以评估姜黄和姜黄素在心血管疾病(CVD)风险的患者降低血脂中的疗效和安全性。在PubMed,Embase,Ovid,Medline和Cochrane图书馆数据库上进行了全面的文献搜索,以确定随机对照试验(截至2016年11月发布),评估姜黄和姜黄素对血脂水平的影响,包括总胆固醇(TC),低 - 密度脂蛋白胆固醇(LDL-C),高密度脂蛋白胆固醇(HDL-C)和甘油三酯(Tg)。使用95%置信区间(CI)的汇集标准化平均差异(SMD)评估效果。分析包括7项合格研究(649名患者)。姜黄和姜黄素显着降低血清LDL-C(SMD?=α - 0.340,95%置信区间[CI]:-0.530至-0.150,P?<0.0001)和Tg(SMD?=? - 0.214,95%CI :与对照组中的相比,:-0.369至-0.059,p?= 0.007)水平。这些可能有效降低代谢综合征患者的血清TC水平(METS,SMD?=? - 0.934,95%CI:-1.289至-0.579,P?<0.0001),姜黄提取物可能具有更大的效果减少血清TC水平(SMD?=? - 0.584,95%CI:-0.980至-0.188,p?= 0.004);但是,效果尚待确认。血清HDL-C水平明显改善。姜黄和姜黄素出现了安全的,并且在任何内容的研究中没有报告严重的不良事件。姜黄和姜黄素可以通过改善血清脂质水平来保护患者面临CVD的风险。姜黄素可以用作常规药物良好的饮食辅助药物。需要进一步的研究来解决与姜黄素的剂型,剂量和药物频率有关的不确定性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号